Sammenligning av effektene av smart app-assistert super-sakte jogging og stasjonær sykling på respirasjonsfunksjon og aerob kapasitet hos høyskole- og universitetsstudenter
Sammenligning av effektene av smartapp-assistert super-langsom jogging og stasjonær sykling på respirasjonsfunksjon og aerob kondisjon hos studenter
As health awareness continues to rise, more people are prioritizing exercise to improve physical condition and enhance overall fitness. For those lacking exercise habits, selecting a simple, accessible, and effective workout becomes crucial. Against a backdrop of prolonged sitting and inactivity, "super slow jogging" is gaining attention. This aerobic exercise involves a slow walking pace and low intensity, yet burns more calories than regular walking, making it an ideal entry-level activity for beginners or those with lower fitness levels. This study aims to investigate whether incorporating super slow jogging training can effectively enhance cardiorespiratory fitness and respiratory function, comparing its outcomes with other exercise types. The purpose of this experiment is academic research, primarily exploring the impact of exercise intervention on physiological functions. It is not intended for health screening or medical diagnosis.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Daliao
-
Kaohsiung City, Daliao, Taiwan, 831301
- No. 151, Jinxue Rd.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- required no regular exercise training in the past six months
- ability to safely perform high-intensity cycling exercise
Exclusion Criteria:
- musculoskeletal limitations that prevented cycling exercise
- recent infection
- known cardiopulmonary disease or medical history affecting cardiovascular or respiratory function
- smoking
- use of medications that may influence cardiopulmonary responses to exercise
- other contraindications to exercise testing according to the American College of Sports Medicine (ACSM) guidelines
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Super slow jogging
A smart app will provide pacing assistance, adjusting step frequency weekly: Week 1: 150 steps per minute Week 2: 180 steps per minute Week 3: 190 steps per minute Week 4: 200 steps per minute |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
|
Eksperimentell: moderate exercise training
Continuous cycling training at moderate intensity of 60% VO₂max |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
|
Placebo komparator: Control
not perform any exercise training |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cardiopulmonary Fitness
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
VO2max (ml/kg/mL) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
Age (yr) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
VEmax (L/min) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
AT% (%VO₂max) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
Resting O₂ pulse (mL·beat-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
Max O₂ pulse (mL·beat-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
MIP (cmH2O) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
MEP (cmH2O) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
Height (cm) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
Weight (kg) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
BMI (kg/m²) |
Before intervention and the end of intervention at 12 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Lung function
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
FEV1 (L) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
FVC (L) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
FEV₁/FVC (%) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
FEF25-75% (L·s-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
PEF (L·min-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
MVV (L·min-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
Breathing reserve (%) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Tidsramme: Before intervention and the end of intervention at 12 weeks
|
Dynamic Index (DI%) |
Before intervention and the end of intervention at 12 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 114-0561
- 114-2813-C-242-003-B (Annet stipend/finansieringsnummer: National Science and Technology Council, Taiwan)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .